Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SLN
SellHot AirSilence Therapeutics plc · Healthcare · United Kingdom · $834M · Avg Vol: $20M/d
24
StockRankGet insider-trade alerts
Q
23
V
20
M
69
P/E (TTM)
—
ROE
-90.4%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.7M | 31.6M | 43.3M | 0.6M | -70.4% | 0.6M | 0.4M | 1.0M | 33.9% |
| EPS | -3.56 | -3.70 | -2.97 | -5.67 | — | -1.29 | -0.73 | -0.77 | — |
| Shares | 47.2M | 47.2M | 47.2M | 47.2M | 0.0% | 62.2M | — | — | — |
| Debt | 0.5M | 0.3M | 0.1M | 0.2M | -33.3% | 0.1M | — | — | — |
| Equity | 26.7M | 22.0M | 134.0M | 62.3M | 32.6% | — | — | — | — |
| Op CF | -57.0M | -49.5M | -67.6M | -62.3M | — | -42.3M | — | — | — |
| Inv CF | -20.5M | 19.3M | -22.0M | -48.0M | — | — | — | — | — |
| Fin CF | 52.6M | 31.9M | 142.1M | 15.0K | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+14.5%
SMA 50SMA 200
Close
$13.31
RSI (14)
51.9
52W High
$17.58
From 52W High
0.8%
SCORE BREAKDOWN
Quality
23
ROIC
-65.4%11.2
ROE
-90.4%10.7
GP/Assets
0.4%11.4
Op. Margin
-10475.6%2.1
FCF/Assets
-47.4%7.2
Piotroski
25.9
Int. Cover
—N/A
D/E Ratio
0.00x91.0
Current Ratio
7.42x82.0
Value
20
P/E (TTM)
—N/A
EV/EBITDA
-9.7x25.0
P/FCF
—N/A
P/B
17.9x6.2
P/S
1474.5x2.0
Div Yield
—N/A
Momentum
69
52W High %
76%61.6
RS 6M
78%95.4
SMA 50/200
1.57x98.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+41%49.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$834M
P/E (Forward)
-19.1x
Gross Margin
85.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SLN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SLN | Silence Therapeutics plc(you) | $834M | 24 | Sell |
| OXB.L | Oxford Biomedica plc | $859M | 14 | Strong Sell |
| AUTL | Autolus Therapeutics plc | $623M | 30 | Sell |
| IMCR | Immunocore Holdings plc | $1.9B | 17 | Strong Sell |
| AVCT.L | Avacta Group Plc | $433M | 10 | Strong Sell |
| ONT.L | Oxford Nanopore Technologies plc | $2.3B | 32 | Sell |
| BCYC | Bicycle Therapeutics plc | $294M | 10 | Strong Sell |
| POLB.L | Poolbeg Pharma PLC | $89M | 25 | Sell |
| 4BB.L | 4basebio PLC | $110M | 10 | Strong Sell |
| GNS.L | Genus plc | $2.1B | 61 | Hold |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 55.3%